APOG News - Candlesense

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis

Could the APEX Phase 2 data lead to analyst upgrades or target‑price revisions for APOG? Are there any competitive developments in the anti‑IL‑13 or atopic dermatitis space that could offset Apogee’s potential best‑in‑class claim? How might the 70 sentiment score influence short‑term market perception and potential price volatility?

Earnings

13 days ago

Apogee Enterprises Appoints Two New Business Segment Presidents

MINNEAPOLIS--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a var...

Could this leadership change precede any broader corporate actions, such as M&A activity, divestitures, or a strategic realignment? Are there any changes to compensation, equity grants, or retention incentives associated with the new appointment that could affect shareholder dilution? How does the market’s perception of management stability affect analyst ratings and target price for APOG?

Leadership

17 days ago

Apogee Enterprises Announces Date for Fiscal 2026 First Quarter Results

MINNEAPOLIS--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a var...

Earnings

2 months ago